Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

API – Small Molecule

80 Articles available
3D Printing

Aprecia and Cycle Team to Develop 3D-Printed Orphan Drugs

PAO-M12-17-NI-018
CDMO

Alcami to Manufacture Darinaparsin

PAO-M11-17-NI-016
API

Right-First-Time Innovation Approach Drives Continual Investment

PAP-Q4-17-CL-003
API

Achieving Efficient Pharmaceutical Synthesis with Process Intensification

PAP-Q4-17-CL-003
API

Becoming Bioavailable

MCO-M07-17-NI-021
API

Cambrex Invests in New Highly Potent API Manufacturing Capacity

PAO-M08-17-NI-016
Biologics

Propagating a Full Spectrum of Services for ADC Development and Manufacture

PAP-Q2-17-CL-007
API

Optimizing API Production as a True Manufacturing Partner

PAP-Q2-17-CL-009
API

Small Molecule Injectable Manufacturing: Challenges and Complexities

PAP-Q2-17-CL-013
Innovation

Flow Chemistry: Pathway for Continuous API Manufacturing

SCM-M05-NI-023
Innovation

Pharma’s Great Automation Migration

PMP-M05-17-NI-001
API

Connecting the Dots for Clients

Michael Hughey, Sales Manager, ACIC Machinery

 

PTV-M03-17-IN-009
Regulatory

Anticipating Future Guidelines By Utilizing The Latest Technologies In Particle Characterization

POP-M03-17-NI-001
API

MicroJet Reactor (MJR) for APIs

Michelle Hall, Marketing Director, CoreRx

PTV-M11-16-AP-028
API

Filling a Market Need

Abby Thompson, Global Marketing Communications Manager, Corden Pharma

PTV-M11-16-AP-016
Industry Leader

Energizing Client Portfolios with Patient-Friendly Dosage Forms

PAP-Q1-17-CL-001
CDMO

Continuous Manufacturing: To Be Continued…

PAP-Q1-17-VP-001
API

Changes in the Wind for the CDMO Market

PAP-Q1-17-FA-002
API

Expanding the Commercial Options for Preparation of Amorphous Solid Dispersions

PAP-Q1-17-CL-006
Excipients

Q: What will be the Impact of the Requirements that Drug Manufacturers Gain a Similar Level of Supply Chain Understanding for Excipients as they Must Have for APIs?

PAP-Q1-17-RT-005
CDMO

Particle Engineering for Improved Bioavailability in Oral Solid Dose Medications

PAP-Q1-17-CL-014
API

Next-Generation OSD Manufacturing Strategy

PAP-Q1-17-CL-015
CDMO

Innovation and Partnership Through Experience and Acquisition

PAP-Q1-17-CL-013
API

Supporting the Pharma Industry Small Business Growth Engine

PAP-Q1-17-CL-017
Regulatory

Experience and Expertise Facilitate Controlled Substance Manufacturing

PAP-Q1-17-CL-004
CDMO

Achieving Security of Supply with Effective Particle Engineering

PAP-Q1-17-CL-002
CDMO

Lifecycle Management Strategies Can Uncover Hidden Value

PMP-M03-17-NI-001
CRO

Spray Drying Enhances Solubility and Bioavailability

PMO-M01-17-NI-001
API

PCAS, Patheon Add New Sites

PAO-M12-16-NI-003
API

The Search for Practical and Economical Catalysts

PTO-M10-16-NI-001
CMO

Something Special: Reporting From CPhI

PAO-M10-16-NI-001
Formulation

Two Promising Small-Molecule Orphan Drugs in Clinical Trials

PAP-Q04-16-TT-001
Formulation

A New Industry Think Tank Forum for Leaders of Outsourced Services and Customers

PAP-Q04-16-NS-001
Biologics

Finding The Ideal Partner for Your Next Biotherapeutic

PAP-Q04-16-CL-013
Formulation

Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services

PAP-Q04-16-CL-004
Drug Delivery

A Look at Recent Pharma Industry Innovations

PAP-Q04-16-NO-001
CDMO

Cultivating a Proactive Quality Culture

PAP-Q04-16-CL-008
Formulation

Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability

PAP-Q04-16-CL-006
CDMO

Capsugel’s Transformation: Q&A with Guido Driesen

PAP-Q04-16-QA-001
API

New Strategies Required to Meet Changing Needs in the Analytical Services Market

PAP-Q04-16-CL-010
CDMO

Meeting Unmet Patient Needs with Small-Volume APIs

PAP-Q04-16-CL-003
API

Targeted, Highly Potent Therapies: Big Growth Driver for the CDMO Market is Here...

SCP-M09-16-NI-001
CDMO

Process Performance Qualification Prep: a Strategic Approach Leads to Success

PAP-Q03-16-CL-008
Equipment

Novel Equipment Solutions: Leading to Manufacturing Efficiency and Productivity

PAP-Q03-16-IR-001
API

Future Pharma Partner Models: Pharma 3.0

PAP-Q03-16-FA-001
API

Joint Venture Contract Services – A CDMO’s Approach to Being a True Partner

PAP-Q03-16-CL-016
Formulation

Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience

PAP-Q03-16-CL-005
CMDO

Creating a Global C‘R’DMO for the Future of (Bio)pharma: Effective Strategies and Tactics

PAP-Q03-16-CL-001
CDMO

Accelerating Approval and Reducing Costs of Spray Dried Drugs through Development by Design (DbD)

PAP-Q03-16-CL-011
API

Biocatalysis Versus Chemocatalysis

MCP-M04-16-NI-001

Quality Culture Wins Over Compliance

PAP-Q02-16-CL-001

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

PAP-Q02-16-CL-007

Bioavailability: What Are Your Thoughts On Enhancing Bioavailability With Novel Technologies?

PAP-Q02-16-RT-001

Accelerating Drug Development and Manufacturing with Engineered Enzymes

PAP-Q02-16-CL-004

Integrating Drug Discovery and Development to Improve Efficiency and Candidate Success

PAP-Q02-16-CL-005
API

Expect Pharmaceutical Contract Manufacturing to Continue Apace in 2016

POP-M03-16-NI-001
Outsourcing

Look for More Outsourcing of Research Activities in 2016

APR-M01-16-NI-002

Strengthening CDMOs to Meet Industry Needs for 2016 and Beyond

PAP-Q1-16-CL-001

Patient Safety and Parenteral Delivery Systems

PAP-Q1-16-CL-010

Strong CMO/CDMO Market Outlook for 2016, but Beware Moderating Factors

PAP-Q1-16-FA-001

Growing Demand for Small-Molecule CDMO Services

PAP-Q1-16-CL-004
API

Good Laboratory Practices Lead to Good Manufacturing in CDMOs

PAP-Q1-16-CL-009

Continuous Processing: Meeting the Need for New Manufacturing Strategies

PAP-Q1-16-CL-005
Biologics

Single-Use Now Key Technology in Biopharmaceutical Manufacturing

POP-M01-16-NI-001
Formulation

Formulation Challenges Drive Interest in CDMOS

MCP-M01-16-NI-001

What Does It Mean to be a Full-Service CDMO?

PAP-Q4-15-CL-002

Risk Minimization through Careful CDMO Selection

PAP-Q4-15-CL-003

Outsourcing Provides Advantages to Sponsor Companies

PAP-Q4-15-CL-001

In-depth Process and Product Expertise – This is Key to CDMO Support of Orphan Drug and Breakthrough Therapy Development & Commercialization

PAP-Q4-15-CL-004

Bolstering Capabilities for Parenteral Drug Development and Manufacturing

PAP-Q4-15-CL-005
CRO

Suiting a Strategy to Fit Biotech Behaviours

MCP-M07-15-NI-001
API

Biologics Account for an Increasing Share of Outsourcing Spending

MCP-M06-15-NI-001
Excipients

Challenges Facing Pharmaceutical Excipients

APR-M05-15-NI-001
Supply Chain

Improving Global Supply Chain Security in the Pharmaceutical Industry

FPP-M04-15-NI-001
Equipment

Trends Impacting Pharma Equipment

PMP-M04-15-NI-001
CMO

Outsourcing Trends in Small Molecule API Manufacturing

LSL-M07-14-NI-001
Biologics

Trends in Outsourcing Solid Dose Manufacturing in 2014

LSL-M03-14-NI-002
API

API Manufacturing: Strategic Partnering Preferences with CMOs Vary Among Small Molecule, High Potency and Biologic API

CIO-M12-13-NI-001
Outsourcing

Competition Yields Benefits for Pharma Companies Outsourcing API Manufacturing

CIO-M05-13-NI-001
CRO

Bringing Order To The Outsourced Manufacturing Space

PC0-M04-11-NI-001
×